Agenus shared a post on LinkedIn:
“Agenus is pleased to share that our Chief Medical Officer, Steven O’Day, M.D., will chair and present at the ESMO Immuno-Oncology Congress (ESMO-IO) in London on December 11, 2025.
Dr. O’Day will moderate the Early Pipelines of Biotech Companies session and deliver a featured lecture on ‘The New Era of CTLA-4 Modulators.’
CTLA-4 targeting has advanced significantly over the past decade. With new engineering strategies, deeper mechanistic insights, and innovative combination approaches, next-generation CTLA-4 modulators are now poised to broaden durable benefit for patients with difficult-to-treat cancers.
Swipe through to view session details, key scientific themes, and Dr. O’Day’s perspective.”
More posts from Agenus.